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Abstract: Adenosine is produced primarily by the metabolism of ATP and mediates its physiological actions by interact-
ing primarily with adenosine receptors (ARs) on the plasma membranes of different cell types in the body. Activation  
of these G protein-coupled receptors promotes activation of diverse cellular signaling pathways that define their tissue-
specific functions. One of the major actions of adenosine is cytoprotection, mediated primarily via two ARs - A1 (A1AR) 
and A3 (A3AR). These ARs protect cells exposed to oxidative stress and are also regulated by oxidative stress. Stress-
mediated regulation of ARs involves two prominent transcription factors - activator protein-1 (AP-1) and nuclear factor 
(NF)-B – that mediate the induction of genes important in cell survival. Mice that are genetically deficient in the   
p50 subunit of NF-B (i.e., p50 knock-out mice) exhibit altered expression of A1AR and A2AAR and demonstrate distinct 
behavioral phenotypes under normal conditions or after drug challenges. These effects suggest an important role for  
NF-B in dictating the level of expression of ARs in vivo, in regulating the cellular responses to stress, and in modifying 
behavior. 
Keywords: Adenosine, adenosine receptor, p50 knockout mice, NF-B, sleep, caffeine.
INTRODUCTION 
  Adenosine is an important inhibitory neuromodulator in 
the central nervous system (CNS). The major source of 
adenosine is ATP, a neurotransmitter or co-transmitter in   
the CNS; in the periphery, ATP is also released from mast 
cells, basophils and endothelial cells as a result of cellular 
damage. Other precursors of adenosine include ADP   
(released in large amounts by activated platelets) and cyclic 
AMP (a second messenger in most cells). Because the   
estimated ratio of ATP:AMP under normoxic condition is 
approximately 50:1, a small decrease in total ATP is   
expected to produce a large increase in concentrations of 
AMP and adenosine [1].  
  Adenine nucleotides are degraded by a series of ectonu-
cleotidases. One such enzyme, 5’-nucleotidase, catalyzes the 
conversion of AMP to adenosine. This enzyme occurs both 
extracellularly (attached to the plasma membrane by glyco-
syl-phosphatidylinositol anchors) and in the cytosol [2]. In 
the CNS, it is located on glia and astrocytes near synaptic 
terminals. Adenosine is rapidly cleared from the extracellular 
space through a bi-directional facilitated transporter and/or 
through metabolism by adenosine deaminase to inosine. In-
hibition of the activity of this transporter leads to increased 
extracellular adenosine and reduced excitatory synaptic 
transmission in rat hippocampal slices [3], affirming a CNS 
depressant action of the nucleoside. 
  AR subtypes include A1, A2a, A2b and A3 [4]. The A2AAR 
is localized to the striatum, where it inhibits dopaminergic 
neurons [5]. Expression of the A3AR is low in rat CNS [6];  
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however, recent findings implicate A3AR in modulating 
CNS injury [7]. The A1AR is the predominant AR subtype in 
the CNS. Autoradiographical studies indicate wide distribu-
tion of the A1AR in CNS, particularly in cortex, hippocam-
pus and thalamus [8]. The A1AR, is the primary mediator of 
the neuroprotective action of adenosine. 
1. ADENOSINE AND ADENOSINE RECEPTORS AND 
CYTOPROTECTION 
  Adenosine is released in response to ischemic stress and 
activates cells in the vicinity of its release site, thus serving a 
paracrine role. Extracellular concentrations of adenosine 
correlate with cerebral blood flow. For example, a transient 
increase in adenosine occurs when flow falls below 25 ml 
100g
–1 min
–1 [9]. Increased adenosine confers protection 
against transient cerebral ischemia. For example, administra-
tion of 2-chloroadenosine protected rats from ischemia-
induced hippocampal cell loss [10]. Another adenosine   
analog, cyclohexyladenosine, protected against cerebral 
ischemia in gerbils [11] and transient ischemia in rats [12].  
Cyclohexyladenosine also provided protection to the hippo-
campus and striatum after 30 min of bilateral carotid occlu-
sion [12]. Rats treated with caffeine, which increases A1AR 
expression in the brain, were more resistant to ischemia,   
underscoring the protective role of this receptor subtype [13]. 
In contrast, prolonged agonist treatment reduced A1AR  
expression and exacerbated the damage created by a subse-
quent ischemic episode [14]. Overall, these studies implicate 
the A1AR in neuroprotection under ischemic conditions. 
  Several mechanisms have been proposed to contribute to 
the cytoprotective role of adenosine. The major mechanism 
involves activation of presynaptic A1AR to decrease release 
of excitatory neurotransmitters such as glutamate [15-17]. 
These presynaptic A1AR activate K
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hyperpolarization [18, 19] and inhibition of Ca
2+ influx into 
the nerve terminal [12]. Such actions reduce neuronal excit-
ability and firing rate [20]. Adenosine-mediated activation of 
a voltage-dependent Cl
- conductance that is distinct from that 
activated by GABA can also contribute to neuronal hyperpo-
larization [21]. Adenosine also acts postsynaptically to re-
duce NMDA receptor-induced synaptic amplification and 
hyperpolarizes astrocytes [22], thereby facilitating glutamate 
uptake by these cells. In addition, adenosine acts as a vasodi-
lator in most vascular beds and augments cerebral blood flow 
[23]. A more delayed protective action of the A1AR is evi-
dent in its role in scar formation and subsequent tissue re-
modeling [24]. 
  In contrast to the A1AR, activation of the A2AAR exacer-
bates neuronal damage, as inferred from various observa-
tions of a protective role of A2AAR blockade in different 
models of ischemia [25-29]. In addition, genetic deletion of 
the A2AAR protected against transient focal brain ischemia in 
mice [30]. The proposed mechanism(s) underlying the pro-
tective action of A2AAR blockade could be broadly classified 
as inhibition of glutamate toxicity and reduction in inflam-
mation. The primary action of A2AAR activation is suggested 
to be a reduction of glutamate transport into [31] or its   
release from astrocytes [32]. The A2AAR has also been   
implicated in the recruitment and activation of microglia in 
the brain in response to injury or stress (for review, see 29), 
supporting therapeutic potential for receptor blockade by 
antagonists. 
  Studies focusing on the A3AR in the brain indicate that 
its activation can cause either protection from or exacerba-
tion of neuronal injury. For example, activation of the A3AR 
reduces ischemic preconditioning and promotes synaptic 
failure produced by oxygen and glucose deprivation in the 
rat hippocampus [7]. This apparent toxicity of A3AR ago-
nists was associated with rapid receptor desensitization after 
the ischemic episode. In contrast, A3AR agonists were pro-
tective after a shorter period of ischemia (2-5 min) in the 
absence of significant A3AR desensitization [33]. However, 
activation of the A3AR reduced ischemic brain damage after 
transient ligation of the middle cerebral artery [34]. The 
A3AR has also been implicated in protecting cultured astro-
cytes from hypoxic damage [35]. The basis of these differing 
roles of the A3AR is not clear, but could be related to the 
degree of receptor activation [36]. Accordingly, a lower level 
of A3AR activation may confer protection, whereas a higher 
level of activation produces cytotoxicity [36]. 
2. ADENOSINE RECEPTOR AND OXIDATIVE 
STRESS 
  Over the past several years, our laboratory has studied 
mechanism(s) underlying the cytoprotective effects of 
adenosine. We have shown that adenosine contributes to 
cytoprotection by enhancing the activities of antioxidant 
enzymes (e.g., superoxide dismutase, catalase and glu-
tathione peroxidase) via activation of their protein kinase C-
mediated phosphorylation [37]. This mechanism could re-
duce the level of reactive oxygen species (ROS), which 
could be harmful to the cell, appears to be relevant in vivo,
and may account for adenosine-induced reduction of lipid 
peroxidation in the cochlea [38]. The nonselective adenosine 
analog (R-phenylisopropyladenosine) protects cochlear ex-
plants from damage induced by cisplatin [39] and chinchilla 
cochlea from noise-induced loss of hair cells, presumably via
the A1AR [40]. Activation of the A1AR also protects against 
cisplatin-induced toxicity [41] and noise-induced hearing 
loss [42]. 
 The  A1AR is responsive to oxidative stress. Not only 
does adenosine suppress ROS generation, but ROS induce 
A1AR expression. This feedback induction of the A1AR
boosts the A1AR response during high oxidative stress and is 
mediated by the stress-regulated transcription factor, nuclear 
factor-B [43]. NF-B-dependent transcription is a novel 
mechanism by which cellular oxidative stress modulates 
A1AR and G protein-coupled receptors. This mechanism 
could influence drug responses in cells under oxidative 
stress. In addition, NF-B has similar influences on A2AAR
expression [44]. Details of these findings and their behav-
ioral manifestations in mice in response to drug challenges 
are discussed below. 
3. NUCLEAR FACTOR B FUNCTION AND REGU-
LATION 
  The transcription factor NF-B, first described for its   
role in the transcription of the immunoglobulin  light chain 
in B lymphocytes [45], mediates gene expression in response 
to a variety of stimuli. The mammalian NF-B family con-
sists of five members, p65 (RelA), RelB, c-Rel, p50/p105 
(NF-B1) and p52/p100 (NF-B2), all of which possess a 
common Rel homology domain [46]. The Rel homology 
domain is a conserved region of 300 amino acids present at 
the N-terminal of these proteins and serves multiple func-
tions, including DNA binding, dimerization, and interaction 
with the inhibitory subunit, IB. The Rel domain also   
contains the nuclear localization sequence that allows   
nuclear translocation of the subunits after NF-B activation 
[47]. In the inactive state, NF-B exists in the cytoplasm   
as a homo- or heterodimer bound to IB. The associated   
IB can become phosphorylated secondary to stimuli that 
activate IB kinase (IKK). Phosphorylation of IB results   
in its ubiquitination and degradation, which releases the   
dimer for nuclear translocation and stimulation of the tran-
scription of genes that contain the decameric B consensus 
sequence.  
  The p65/p50 combination is the most abundant NF-B
dimer in most cells. Other transcriptionally active dimers are 
p65/p65, p50/c-Rel and p65/c-Rel. Some dimer combina-
tions, such as p50/p50 and p52/p52 are believed to be inac-
tive or repressive [48]. However, these dimers can stimulate 
transcription by binding to an IB-like nuclear protein, BCL-
3 [49]. The p50 subunit lacks the transcriptional activation 
domain that is present in p65 and c-Rel subunits, which 
likely accounts for property of transcriptional repression by 
the p50 homodimer [50]. 
  In addition to IB phosphorylation, dissociation, and 
degradation, other mechanisms can activate NF-B. The p-
100 mediated pathway involves an NF-B inducing kinase 
(NIK) and IKK1. IKK1 phosphorylates p100, which leads to 
its ubiquitination and degradation to form the p52 subunit. 
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can enter the nucleus. In a similar fashion, constitutive proc-
essing of p105 to produce p50 occurs in the cytoplasm,   
allowing formation of p50/p50 dimers, which can then enter 
the nucleus [51]. 
4. NUCLEAR FACTOR B REGULATION OF A1AR 
AND A2AAR EXPRESSION 
4.1. Adenosine A1 Receptor 
  Early studies in our laboratories indicated that the A1AR 
is dynamically regulated by oxidative stress. In effect, the 
A1AR serves as a sensor of oxidative stress. These observa-
tions were initially derived from studying the effect of the 
chemotherapeutic agent cisplatin on the expression of A1AR 
in the chinchilla cochlea [38]. Cisplatin damages outer hair 
cells of the cochlea and produces significant hearing loss. 
We observed significant induction of A1AR in the cochlea 
prior to the induction of outer hair cell death. This induction 
likely represents a mechanism for combating, albeit ineffec-
tively, the toxic effect of cisplatin in the cochlea. 
  To delineate the mechanism responsible for A1AR induc-
tion, we examined the role of NF-B, which is known to be 
induced by oxidative stress. Using the inhibitor pyrrolidine 
dithiocarbamate (PDTC), we showed that cisplatin-induced 
induction of A1AR was directly related to activation of NF-
B. Induction of the A1AR also occurred in response to other 
chemotherapeutic agents (e.g., doxorubicin, mitroxantrone) 
that increase the production of ROS. Cisplatin-induced 
A1AR induction in cells was blunted by incubation with the 
ROS scavenger catalase or the inhibition of NF-B with 
dexamethasone. Examination of the promoter of the human 
A1AR gene suggested the presence of an NF- B consensus 
sequence located 623 base pairs upstream of the start site of 
promoter A construct (pBLPnif/PmtA) [52]. Transfection of 
a plasmid construct containing this promoter and firefly lu-
ciferase reporter gene in ductus deferens tumor (DDT) cells 
allowed us to demonstrate NF-B dependent regulation of 
promoter activity [43]. These data suggest that oxidative 
stress, through activation of NF-B, could induce the expres-
sion of the A1AR. Such a process would likely aid in cytopro-
tection under conditions of increased oxidative stress. 
 A 1AR are also induced in response to other conditions 
associated with oxidative stress and inflammation. For ex-
ample, A1AR mRNA and protein increased in brain after the 
induction of cerebral ischemia in rats [53]. In addition, nitric 
oxide acts through NF-B to increase A1AR expression in a 
pheochromocytoma cell line (PC12 cells) and in isolated 
cortical neurons [54]. Noise exposure, which is associated 
with increased NADPH oxidase activity in the chinchilla 
cochlea, is also linked to the induction of the A1AR in the 
inner ear [55]. A1AR and A3AR were also induced in the gut 
in a rabbit model of ileitis [56], and A1AR was induced in 
kidney in association with oxidative stress produced by os-
motic diuresis [57]. 
4.2. Adenosine A2A Receptor 
  Gene expression profiling in PC12 cells demonstrated 
that exposure to nerve growth factor (NGF) significantly 
reduced the expression of the A2AAR gene. The initial study 
reported a 3-fold decrease in A2AAR within 3 days of NGF 
treatment [58]. Further studies demonstrated that NGF 
caused rapid activation of NF-B via the low affinity p75 
NGF receptor, with a resultant reduction in A2AAR [44]. 
This response was mimicked by agents that activate NF-B
(e.g., ceramide, H2O2) [44]. These results support a func-
tional role for the NF-B consensus sites present in the 
A2AAR gene promoter [59]. Other mechanisms for NGF regu-
lation of A2AAR depend on TrkA-, Src-, and Ras and are 
linked to the activation of extracellular regulated kinase and 
stress-activated protein kinase/c-Jun NH(2)-terminal kinase 
[60]. The involvement of multiple pathways in the regulation 
of the A2AAR by NGF may indicate different temporal pro-
files of activation of these pathways during development. In 
addition, the p75/NF-B pathway could provide a general 
mechanism for control of A2AAR expression by neurotrophins 
that do not use TrkA for signaling (e.g., brain-derived neu-
rotrophic factor). 
5. A1AR EXPRESSION AND FUNCTION IN P50 
KNOCKOUT MICE 
  To evaluate the significance of NF-B in the regulation 
of the A1AR expression, we used mice with deletion of the 
gene for the p50 subunit of NF-B. Although this gene 
knock-out (KO) renders these mice immune deficient, they 
are viable and able to reproduce [61]. However, deletion of 
the p65 subunit of NF-B is embryonically lethal. Deletions 
of p65 can therefore generally be assessed only in vitro [62]. 
5.1. Biochemical Characterization 
  Brain cortical plasma membranes prepared from p50 KO 
mice demonstrated significant reductions in the levels of the 
A1AR, as determined by radioligand binding assays, Western 
blotting, immunohistochemistry, and real time polymerase 
chain reactions (PCR) [63] (Fig. 1). Similar reductions in 
A1AR were measured in the hippocampus, brain stem, hypo-
thalamus and peripheral tissues (adrenal gland, kidney and 
spleen) Fig. (1). Levels of the guanine nucleotide coupling 
proteins (G proteins) alpha subunits (G i3) were also signifi-
cantly reduced in the p50 KO mice, although the levels of 
G i1 were not changed, suggesting deficits in multiple com-
ponents of the A1AR signaling cascade. Functionally, the 
deficit in A1AR/Gi protein expression was associated with 
reduced protection of neurons from apoptosis [63]. Overall, 
these findings suggest that activation of NF-B is essential 
for maintaining normal A1AR expression and function and 
for survival of neurons in culture. Thus, A1AR promotes 
neuronal survival. 
5.2. Sleep
  Adenosine and AR have been extensively studied for 
their involvement in the regulation of sleep and wakefulness. 
Previous studies established adenosine as a sleep-inducing 
factor that increases in the basal forebrain during prolonged 
wakefulness [64]. Similarly, reduced expression of A1AR in 
the magnocellular cholinergic region of the basal forebrain 
by antisense oligonucleotides alters sleep [65]. However, 
recent studies indicate a complex role for A1AR in mediating 
sleep and arousal. For example, evaluation of A1AR and 
A2AAR KO mice showed that caffeine promotes arousal 
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However, a subsequent study by the same group found that 
activation of the A1AR in the tuberomammillary nucleus 
could mediate non-rapid eye movement (non-REM) sleep 
through suppression of histamine release [67]. 
  We evaluated p50 KO mice to determine whether their 
deficit in the A1AR would affect sleep (Fig. 2). The p50 KO 
mice had more slow wave and rapid eye movement (REM) 
sleep under normal conditions than did wild type mice 
(B6129PF2/J strain) [68]. This finding was surprising, be-
cause based on the purported role of the A1AR in regulating 
sleep in rats [65], less A1AR expression should be associated 
with reduced sleep duration. Dysregulation of another AR 
(such as the A2AAR) or other factors (such as increased in-
flammatory cytokine or prostaglandin D2 production) in the 
p50 KO mice could account for this finding. In addition, p50 
KO mice showed an accelerated return to normal sleep after 
sleep deprivation. Finally, p50 KO mice showed a greater 
suppression of SWS after administration of bacterial 
lipopolysaccharide (LPS) challenge. These data support a 
role of NF-B in regulating normal sleep and mediating the 
responses to sleep deprivation and immune challenge. How-
ever, the involvement of AR in mediating the sleep profiles 
of p50 KO mice remains undetermined.  
  In addition to differences in sleep, the p50 KO mice gen-
erally exhibited lower core body temperatures than did the 
wild-type mice. LPS produced a transient hyperthermia in 
wild type mice, but persistent hypothermia in p50 KO mice 
[68]. This finding suggests that the p50 KO mice either 
lacked a normal homeostatic response to hypothermia or 
developed a more prolonged and severe response to LPS, in 
either case implicating NF-B in the normal reaction. This 
finding is also interesting in light of a reported temperature-
Fig. (1). A1AR in brain of p50 KO mice. (A) A1AR binding in F2 and p50 KO mice (n = 4 per strain) was quantified in membrane fractions 
of cortex, hippocampus, brain stem, and hypothalamus using the specific A1AR antagonist [
3H]-DPCPX (1 nM). Values are expressed as 
fmol/mg protein and represent mean ± S.E.M. for three independent experiments with samples assayed in triplicate (* p < 0.05, Student’s t-
test). (B) Saturation binding analysis of cortical membrane for A1AR with [
3H]-DPCPX in the absence (total binding) or presence (nonspe-
cific binding) of 0.5 mM theophylline (n = 5 per strain). Curves were fitted to a one-site model using GraphPad Prism. Modified from 
Jhaveri et al., 2007, Neuroscience 146, 415-426, with permission from Elsevier. 
Fig. (2). Patterns of sleep in B6129PF2/J (wild type) and p50 knockout (KO) mice. The amount of time spent in slow-wave sleep (SWS; 
A) and rapid-eye-movement sleep (REMS; B) are expressed as percentage of recording time spent in each state. Delta wave amplitude  
during SWS (C) is expressed as a percentage of mean values measured over the entire 24 h recording period. The black bar along the x-axis 
denotes the dark phase of the diurnal cycle. Solid circles, F2 (wild-type) mice (n = 16); open circles, p50 KO mice (n =14). Each datum point 
denotes a 2-h average ± S.E.M. *Significance at the specified time point (p < 0.05 by ANOVA and independent Student’s t-test). Modified 
from Jhaveri et al. (2006), Am J Physiol Regul Integr Comp Physiol 291, R1516-1526, with permission from the American Physiological 
Society. 
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dependent activation of NF-B in mouse liver [69]. LPS-
stimulated TNF- levels were higher in p50 KO versus the 
wild type mice, which could also contribute to the persistent 
hypothermia observed in the p50 KO mice.  
6. A2AAR EXPRESSION AND FUNCTION IN P50
-/-
MICE 
6.1. Biochemical Characterization 
 A 2AAR expression in brain is localized largely in the 
striatum. Striatal A2AAR, together with dopamine D2 recep-
tor (D2R), participates in the control of locomotor activity. 
These receptors demonstrate mutual antagonistic actions by 
physically interacting with each other and differentially 
modulating post-receptor signal transduction pathways. As 
such, inhibition of the A2AAR by caffeine promotes hyperac-
tivity by reducing adenosine inhibition of D2R function. Re-
cent in vitro evidence indicates that expression of the A2AAR 
[44] and the D2R [70] are differentially regulated by NF-B, 
highlighting another potential difference between these two 
receptors. To extend these observations, we evaluated the in
vivo regulation of these receptors using p50 KO mice, with 
the wild type B6129PF2/J (F2) mice serving as controls   
(Fig. 3). Quantification of adenosine receptor (AR) subtypes 
in striata from p50 KO mice using PCR, radioligand binding 
assays and immunocytochemistry showed more A2AAR 
mRNA and protein, but less A1AR mRNA and protein as 
compared with F2 mice. Striata from p50 KO mice also 
showed less D2R mRNA and [
3H]-methylspiperone binding 
[71]. These studies suggest that absence of the NF-B p50 
subunit leads to dysregulation of ARs and D2R in the stria-
tum, as observed for the A1AR in other brain regions. Over-
all, these studies suggest a role of the NF-B p50 subunit 
and/or the composition of the heterodimers in regulation of 
striatal A1AR, A2AAR and D2R. 
6.2. Caffeine-Induced Locomotor Activation 
  Alterations in the balance of A2AAR and D2R function in 
striatum could alter locomotor activity. Although F2 and p50 
KO mice did not differ in terms of basal locomotor activity, 
the p50 KO mice demonstrated hypersensitivity to caffeine-
induced behavioral activation during the dark phase (when 
mice are normally active) but not during the light phase 
(when mice are normally asleep) (Fig. 4) [72]. Similarly, p50 
KO mice showed behavioral hypersensitivity to intraperito-
neal injections of SCH58261, an A2AAR antagonist [72]. In 
contrast, intraperitoneal injections of the selective A1AR 
antagonist, DPCPX, increased locomotor activity in both F2 
and p50 KO mice, indicating that the increased sensitivity of 
p50 KO mice to caffeine likely did not involve the A1AR. 
The intraperitoneal administration of a combination of SCH 
58261 and DPCPX produced an apparent synergistic in-
crease in locomotor activity in both strains of mice. Admini-
stration of the D2R antagonist, raclopride, reduced the stimu-
latory effect of SCH58261 on locomotor activity. This latter 
finding suggests an involvement of D2R activation in mediat-
ing locomotor activation after A2AAR blockade. The locomo-
tor activity data support several conclusions: 1) the p50 KO 
mice are more sensitive to A2AAR antagonists than are wild 
type F2 mice, 2) the higher striatal A2AAR in KO mice could 
provide a larger striatal target for inhibition by caffeine, thus 
accounting for the heightened behavioral sensitivity and 3) 
the increased sensitivity to A2AAR antagonists results, at 
least in part, from increased D2R activity. 
 
 
 
 
 
 
 
 
 
 
Fig. (3). A2AAR in striata of p50 KO versus F2 mice. (A) Real time PCR (A; n = 10 per group). (B) Traditional PCR (n = 2 per group). (C) 
Saturation curves with inset. Scatchard plot for 
125I-ZM241385 binding to A2AAR in mouse crude striatal membranes. The plots shown rep-
resent pooled striata from 4 mice, with samples at each concentration assayed in triplicate. This analysis was repeated on 3 different pooled 
samples with similar results. (D) Affinity purification of the A2AAR from F2 and p50 KO striata (n = 4 per strain). E) Immunohistochemistry 
of striatal A2AAR from F2 and p50 KO mice (n=4 per strain). Arrowheads depict specific A2AAR-immunolabeled neurons. The sections  
represent a 400-fold magnification of the image. Scale bar represents 10  m. Reprinted from Xie et al., 2007, Life Sci 81, 1031-1041, with 
permission from Elsevier. Nuclear Factor B and Adenosine Receptors  Current Neuropharmacology, 2011, Vol. 9, No. 2    347
7. CONCLUSION 
 NF-B plays a significant role in the regulation of genes 
involved in response to immune activation and oxidative 
stress. To date, only a few studies have detailed the involve-
ment of this transcription factor in regulation of G protein 
coupled receptors. In this review, we describe differential 
regulation of the A1AR and A2AAR by NF-B and show that 
these receptors are differentially expressed in mice deficient 
in the p50 subunit of NF-B. Behavioral studies performed 
on these mice suggest a role for the p50 subunit and the 
A1AR in the regulation of normal sleep, the response to sleep 
deprivation, and the sleep patterns that develop after an im-
mune challenge. The p50 KO mice also show behavioral 
sensitivity to caffeine and A2AAR antagonists, which may be 
related to the greater expression of the A2AAR in the striatum 
and possibly to increased dopamine release and D2R activity 
in the KO mice (Fig. 5). However, the potential for various 
A1AR, A2AAR and D2R heterodimer combinations [73] with 
different functions in the striatum of the p50 KO mice com-
plicates interpretation of their behavioral hypersensitivity to 
caffeine. Nevertheless, the p50 KO mice could provide a 
useful model for studying the expression and integration of 
multiple NF-B targets in the regulation of behavior. 
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